GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Kiadis Pharma NV (GREY:KIADF) » Definitions » Operating Margin %

Kiadis Pharma NV (Kiadis Pharma NV) Operating Margin % : -81.36% (As of Dec. 2020)


View and export this data going back to 2016. Start your Free Trial

What is Kiadis Pharma NV Operating Margin %?

Operating Margin % is calculated as Operating Income divided by its Revenue. Kiadis Pharma NV's Operating Income for the six months ended in Dec. 2020 was $-17.32 Mil. Kiadis Pharma NV's Revenue for the six months ended in Dec. 2020 was $21.29 Mil. Therefore, Kiadis Pharma NV's Operating Margin % for the quarter that ended in Dec. 2020 was -81.36%.

The historical rank and industry rank for Kiadis Pharma NV's Operating Margin % or its related term are showing as below:

KIADF' s Operating Margin % Range Over the Past 10 Years
Min: -194.89   Med: -194.89   Max: -194.89
Current: -194.89


KIADF's Operating Margin % is not ranked
in the Biotechnology industry.
Industry Median: -171.86 vs KIADF: -194.89

Kiadis Pharma NV's 5-Year Average Operating Margin % Growth Rate was 0.00% per year.

Kiadis Pharma NV's Operating Income for the six months ended in Dec. 2020 was $-17.32 Mil. Its Operating Income for the trailing twelve months (TTM) ended in Dec. 2020 was $-39.69 Mil.


Kiadis Pharma NV Operating Margin % Historical Data

The historical data trend for Kiadis Pharma NV's Operating Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kiadis Pharma NV Operating Margin % Chart

Kiadis Pharma NV Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20
Operating Margin %
Get a 7-Day Free Trial Premium Member Only - - - - -194.88

Kiadis Pharma NV Semi-Annual Data
Dec12 Dec13 Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20
Operating Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -81.36

Competitive Comparison of Kiadis Pharma NV's Operating Margin %

For the Biotechnology subindustry, Kiadis Pharma NV's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kiadis Pharma NV's Operating Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kiadis Pharma NV's Operating Margin % distribution charts can be found below:

* The bar in red indicates where Kiadis Pharma NV's Operating Margin % falls into.



Kiadis Pharma NV Operating Margin % Calculation

Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.

Kiadis Pharma NV's Operating Margin % for the fiscal year that ended in Dec. 2020 is calculated as

Operating Margin %=Operating Income (A: Dec. 2020 ) / Revenue (A: Dec. 2020 )
=-41.49 / 21.29
=-194.88 %

Kiadis Pharma NV's Operating Margin % for the quarter that ended in Dec. 2020 is calculated as

Operating Margin %=Operating Income (Q: Dec. 2020 ) / Revenue (Q: Dec. 2020 )
=-17.321 / 21.29
=-81.36 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kiadis Pharma NV  (GREY:KIADF) Operating Margin % Explanation

Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.


Be Aware

Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).

If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.

For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokia’s Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).

Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.


Kiadis Pharma NV Operating Margin % Related Terms

Thank you for viewing the detailed overview of Kiadis Pharma NV's Operating Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Kiadis Pharma NV (Kiadis Pharma NV) Business Description

Traded in Other Exchanges
N/A
Address
Paasheuvelweg 25A, Amsterdam, NLD, 1105 BP
Kiadis Pharma NV is a Netherlands based clinical-stage biopharmaceutical company. It is focused on research, development, and commercialization of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. The company's product pipeline includes K-NK002, K-NK003, K-NK00X, and others.

Kiadis Pharma NV (Kiadis Pharma NV) Headlines

No Headlines